share_log

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

Stephens & Co. 启动对catalyst pharmaceuticals的覆盖,给出超配评级,宣布目标价为35美元。
Benzinga ·  11/18 23:28  · 评级/大行评级

Stephens & Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight rating and announces Price Target of $35.

Stephens & Co. 分析师苏丹·洛根纳桑对catalyst pharmaceuticals(纳斯达克:CPRX)首次进行覆盖,给予超配评级,并宣布价格目标为35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发